MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evaluation of dose rate of photobiomodulation (light) therapy in patients with Parkinson’s Disease: Double blind placebo-controlled pilot trial. Is there a dose frequency per week that influences quality of life, mobility and cognition?

J. Bullock-Saxton, L. Laakso, A. Lehn, F. Read, K. Harm, A. Gosling, S. Hardy, P. Newcombe, A. Nolan, E. Tune (Brisbane, Australia)

Meeting: 2019 International Congress

Abstract Number: 812

Keywords: Interventions, Parkinsonism

Session Information

Date: Tuesday, September 24, 2019

Session Title: Parkinsonisms and Parkinson-Plus

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: This assessor- and participant-blinded placebo-controlled pilot study aimed to evaluate the influence on motor outcomes associated with Parkinson’s Disease with different dose application regimens of PBMt.

Background: Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder with movement (motor) decline and non-motor symptoms such as cognitive effects and sleep disturbance. PD is not curable and the cause is not clear. One hypothesis is that PD develops because of mitochondrial dysfunction.  Photobiomodulation therapy (PBMt) stimulates mitochondrial action by absorption of photons in specific transmembrane proteins (cytochrome c oxidase), resulting in a range of physiological effects that may be beneficial to cerebral function.

Method: Twenty (20) participants with PD diagnosed by a movement disorders specialist Neurologist volunteered to participate.  Participants were randomly allocated to one of two treatment groups.  All treatment groups visited the clinic 3/week for 4 weeks, had a 4 week wash-out and then repeated the same schedule.  In the first phase, one group received 3 treatments/week and the other received 3 placebo treatments/week.  In the second phase, the treatment dose was either a) 1 treatment and 2 sham/week or b) 2 treatments and 1 sham/week.  The PBMt protocol used an Irradia 60W, 904 nm laser (pulse mode: 4 x 60mW; total output power: 4 x 240mW) to 6 areas on the cranium (frontal, temporal left and right, crown, occiput and soft palate.  Placebo applications were made to the same locations using a placebo device of identical appearance.  A wide range of non motor and upper limb and lower limb motor outcomes were assessed pre and post intervention.  This paper describes the results for objective physical outcome measures for PD.

Results: Upper limb tests of 9 Hole Peg test and timed Spiral tests demonstrated significant (p<0.05) improvement with PBMt.  Dynamic balance tests improved for the treatment group that had 3/wkly PBMt followed by 1/wkly PBMt.

Conclusion: PBMt influenced some aspects of upper and lower limb motor function, particularly when administered at a more frequent rate of application initially followed by a reduction in dosing.

To cite this abstract in AMA style:

J. Bullock-Saxton, L. Laakso, A. Lehn, F. Read, K. Harm, A. Gosling, S. Hardy, P. Newcombe, A. Nolan, E. Tune. Evaluation of dose rate of photobiomodulation (light) therapy in patients with Parkinson’s Disease: Double blind placebo-controlled pilot trial. Is there a dose frequency per week that influences quality of life, mobility and cognition? [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/evaluation-of-dose-rate-of-photobiomodulation-light-therapy-in-patients-with-parkinsons-disease-double-blind-placebo-controlled-pilot-trial-is-there-a-dose-frequency-per-week-that-influen/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-of-dose-rate-of-photobiomodulation-light-therapy-in-patients-with-parkinsons-disease-double-blind-placebo-controlled-pilot-trial-is-there-a-dose-frequency-per-week-that-influen/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley